KRRO

Korro Bio, Inc.
—

Company Information

Company Name
Korro Bio, Inc.
CIK
CIK0001703647
Category
Non-accelerated filer<br>Smaller reporting company
Ticker: Exchange
KRRO: Nasdaq
Fiscal Year End
December 31
Owner Organization
03 Life Sciences
SIC
2834
SIC Description
Pharmaceutical Preparations
Ticker
KRRO

SEC filing data through

Insider Sentiment

Last purchase
2026-08-10
Last sale
2026-09-14
Shares purchased (TTM)
1,865,882
Shares sold (TTM)
167,565
Buy ratio (TTM)91.8%

Institutional Sentiment

As of
2026-06-30
Institutional shares owned
14,012,864
Shares outstanding
17,618,441
Ownership
79.54%
-16.81% Y/Y

Earnings Market Reaction

Filing date
2026-11-05
Price on filing date
—
1-month reaction
Pending
3-month reaction
Pending
Drift continued5/11 (45%)
Faded / reversed6/11 (55%)

Balance Sheet

Values in millions ($)
Line item2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-312023-12-31Subscriber-only columnSubscriber-only columnSubscriber-only columnSubscriber-only columnSubscriber-only columnTrend
Assets
Cash And Cash Equivalents At Carrying Value40256222243464566391139166
Marketable Securities Current65905253686351707466-0
Assets Current
Assets Current1091211208298103121132153164146173
Short Term Investments-----------0
Accounts And Other Receivables Net Current0001112210--0
Restricted Cash Current---1--002244
Prepaid Expense And Other Assets Current466655444433
Property Plant And Equipment Net77882425272829252116
Operating Lease Right Of Use Asset78882324242424252627
Restricted Cash Equivalents Noncurrent222222333333
Marketable Securities Noncurrent20234310102324373230-0
Other Assets Noncurrent222233332323
Assets148163184114162180202226244250198222
Liabilities
Accounts Payable Current342225446657
Accrued Liabilities Current65108664656510
Liabilities Current
Liabilities Current151315121517131514121119
Operating Lease Liability Current333332210012
Deferred Revenue Current310034342--0
Operating Lease Liability Noncurrent383940414242434342383531
Deferred Revenue Noncurrent578855668--0
Other Liabilities Noncurrent221121111111
Liabilities606064626365636664524752
Preferred Stock Value000000000000
Common Stock Value000000000000
Stockholders Equity
Additional Paid In Capital541526523435433431429427424422354353
Stockholders Equity881031205199115139160180198151170
Accumulated Other Comprehensive Income Loss Net Of Tax-0-000000010-0
Retained Earnings Accumulated Deficit-440-422-403-384-334-316-290-267-245-224-203-183
Liabilities And Stockholders Equity148163184114162180202226244250198222
Preferred Stock Par Or Stated Value Per Share0.000.000.000.000.000.000.000.000.000.000.000.00
Preferred Stock Shares Authorized101010101010101010101010
Preferred Stock Shares Issued000000000000
Preferred Stock Shares Outstanding000000000000
Common Stock Par Or Stated Value Per Share0.000.000.000.000.000.000.000.000.000.000.000.00
Common Stock Shares Authorized200200200200200200200200200200200200
Common Stock Shares Issued151514999999988
Shares Outstanding141514999999988

Select a line item above to chart it.

Recent filings

Financial statements beyond 3 years are for subscribers only.

Unlock 17+ years of income statements, balance sheets, and cash flow statements

Start 7-day free trial

Korro Bio, Inc. (KRRO) — SEC Financial Statements & Analysis

Korro Bio, Inc. (KRRO) is a pharmaceutical preparations company, incorporated in DE. Korro Bio, Inc. trades on Nasdaq as: KRRO. Korro Bio, Inc. (KRRO)'s most recent SEC filing is a Form 10-Q for the period ended 2026-09-30, filed with the SEC on 2026-11-05. Based on that filing, Korro Bio, Inc. carries a market cap of $177.06M, a P/E ratio of -1.67x, a P/B ratio of 2.00x, a P/S ratio of 137.05x, an enterprise value of $136.85M, and an EV/EBITDA multiple of -1.27x. On profitability, it posts an operating margin of -8467.34%, a net margin of -8214.47%, a Return on Equity (ROE) of -113.26%, a Return on Assets (ROA) of -68.54%, and a Return on Invested Capital (ROIC) of -175.72%. Per share, it reports EPS of $-5.94, diluted EPS of $-5.94, free cash flow per share of $-3.57, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -82.47% year-over-year, net income growth of 20.03% year-over-year, and EPS growth of -36.91% year-over-year. On the balance sheet, it maintains a current ratio of 7.30x, a quick ratio of 7.04x, working capital of $94.01M, a debt-to-equity ratio of 0.68x, a debt ratio of 0.4, an interest coverage ratio of -447.49x, free cash flow of $-63.87M (TTM), and net debt of $-40.22M. Figures sourced from SEC EDGAR.

Market Cap
$177.06M
P/E TTM
-1.67x
EPS TTM
$-5.94
P/B TTM
2.00x
ROE TTM
-113.26%
ROA TTM
-68.54%
Debt To Equity
0.68x
Free Cash Flow TTM
$-63.87M
Net Revenue TTM Growth 1Y
-82.47%

Data as of 2026-09-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Korro Bio, Inc. in?

Korro Bio, Inc. (KRRO) operates in the Pharmaceutical Preparations industry.

What exchange does KRRO trade on?

Korro Bio, Inc. (KRRO) trades on the Nasdaq.

Where is Korro Bio, Inc. incorporated?

Korro Bio, Inc. is incorporated in DE.

When was Korro Bio, Inc. (KRRO)'s most recent SEC filing?

Korro Bio, Inc. (KRRO)'s most recent SEC filing is a Form 10-Q for the period ended 2026-09-30, filed with the SEC on 2026-11-05.

What is KRRO's market cap?

Korro Bio, Inc. (KRRO) has a market capitalization of $177.06M as of 2026-09-30.

What is KRRO's EPS (earnings per share)?

Korro Bio, Inc. (KRRO)'s trailing twelve month EPS is $-5.94 as of 2026-09-30.

What is KRRO's ROE (return on equity)?

Korro Bio, Inc. (KRRO)'s trailing twelve month Return on Equity (ROE) is -113.26% as of 2026-09-30.

What is KRRO's ROA (return on assets)?

Korro Bio, Inc. (KRRO)'s trailing twelve month Return on Assets (ROA) is -68.54% as of 2026-09-30.

What is KRRO's ROIC (return on invested capital)?

Korro Bio, Inc. (KRRO)'s trailing twelve month Return on Invested Capital (ROIC) is -175.72% as of 2026-09-30.

What is KRRO's EV/EBITDA?

Korro Bio, Inc. (KRRO)'s trailing twelve month EV/EBITDA is -1.27x as of 2026-09-30.

Wall Street's data.
Main Street's price.